Funding News Edition: January 09, 2019 See more articles in this edition
NIAID is cosponsoring the funding opportunity announcement (FOA) NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01, Clinical Trial Not Allowed). The FOA’s purpose is to address barriers that hinder translating novel scientific advances into commercially viable diagnostics, devices, therapeutics, and tools that improve patient care and public health.
Carefully read the FOA for full details. We provide you with a few important points below.
If funded, you should participate in a technology development consortium that incorporates best practices from current pilot programs and fulfills the objectives of the Phase 0 Proof of Concept Partnership pilot program. The consortium would come together to enable:
- The infrastructure for identifying the most promising technologies
- Funding for product definition studies provided to individual researchers
- Access to expertise in areas required for early-stage technology development
- Skills development and hands-on experience in entrepreneurship
Note that the REACH program advances Fiscal Year 2020 Administration Research and Development (R&D) Budget Priorities. This includes educating and training a workforce for the 21st century economy, transferring technology from the laboratory to the marketplace, and partnering with industry and academia to advance the U.S. R&D enterprise.
NIH will host a free pre-submission webinar on Wednesday, January 23, 2019, at 1 p.m. Eastern Time. To register, go to REACH Pre-Submission Webinar.
Award and Deadline Details
Participating institutes and centers intend to commit an estimated total of $20 million to fund up to five awards over four years at $1 million per center per year.
Optional letter of intent is due 30 days before the application due date. The application deadline is March 19, 2019, by 5 p.m. local time.
Direct your scientific/research questions to Dr. Kathleen Rousche, the National Heart, Lung, and Blood Institute’s scientific program manager.